Tag: disorders

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

LA JOLLA, Calif., July 31, 2025 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ: MNOV) and the Standard Market of the Tokyo Stock Exchange (Code Number: 4875) (the “Company”), announces a Standby Equity Purchase Agreement (SEPA) for up to $30 million worth of common stock over the course of 36 months.

This Isn’t Rare. It’s Just Overlooked. Let’s Do Better for Kids with Prenatal Substance Exposure

By Mary Kirchoff, CEO of Wonderland Child & Family Services / Hope Rising Clinic BOTHELL, Wash., July 30, 2025 /PRNewswire/ -- A recent article highlighted...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

The THR‑β agonist market is witnessing rapid growth, fueled by the increasing global prevalence of metabolic disorders such as MASH and rare genetic conditions...

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

TEL AVIV, Israel, July 30, 2025 (GLOBE NEWSWIRE) -- SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders of the central nervous system, announces additional progress in connection with the proposed merger with AutoMax Motors Ltd., a leading vehicles importer and the exclusive importer of Anhui Jianghuai Automobile Group Corp., Ltd.-manufactured electric vehicles in Israel (“AutoMax”).

Spineway : H1 2025 results – Continued improvement in results and financial position

Press release

EuMentis Therapeutics Receives U.S. FDA Clearance of IND Application for EM-221, a Novel PDE10A Inhibitor for Schizophrenia

-Company expects to initiate Phase 2 study in 2H 2025- SAN DIEGO, July 30, 2025 /PRNewswire/ -- EuMentis Therapeutics, Inc., ("EuMentis"), a clinical-stage drug development company...

Vystar Introduces New RxAir-800 Replacement Cartridge Extended Life UV-C Bulb

New RxAir400 Pro UV-C bulb replacement cartridge provides 18,000 vs 9,000 hr. use.

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

Freiburg (Germany), Suzhou (China) and Boston (USA), July 30, 2025:

AltaPointe Health Expands Children’s Outpatient Services with New Mobile County Location

MOBILE, Ala., July 29, 2025 /PRNewswire/ -- AltaPointe Health is excited to announce the opening of its newest children's outpatient clinic located at 4211...

FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER’S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS

Key Takeaways At AAIC 2025, the Alzheimer's Association released the first in a series of clinical practice guidelines for the diagnosis, treatment and care of...

- A word from our sponsors -

Newsletter Signup

Name(Required)

First Last

Company Name

Email(Required)

Enter Email Confirm Email

CAPTCHA

Privacy(Required)

I agree with the storage and handling of my data by this website. - Privacy Policy *

Comments

This field is for validation purposes and should be left unchanged.

HomeTagsDisorders

Orbs Launches On-Chain Execution Infrastructure for Institutional Crypto Trading

Prime Minister Carney expands Canada’s partnership with Ireland across science, technology, and culture

ROSEN, NATIONAL TRIAL ATTORNEYS, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action – WGS

Tag: disorders

MediciNova Announces Signing of a Standby Equity Purchase Agreement for up to $30 Million

This Isn’t Rare. It’s Just Overlooked. Let’s Do Better for Kids with Prenatal Substance Exposure

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

THR-β Agonist Market on the Rise: Insights and Projections Upto 2034 | DelveInsight

SciSparc Announces Updates Regarding Proposed Merger; Form F-4 Registration Statement Has Been Declared Effective by SEC

Spineway : H1 2025 results – Continued improvement in results and financial position

EuMentis Therapeutics Receives U.S. FDA Clearance of IND Application for EM-221, a Novel PDE10A Inhibitor for Schizophrenia

Vystar Introduces New RxAir-800 Replacement Cartridge Extended Life UV-C Bulb

Dr. Falk Pharma and Allianthera (Suzhou) Biopharmaceuticals Forge Strategic Partnership for Novel AhR Agonist Development

AltaPointe Health Expands Children’s Outpatient Services with New Mobile County Location

FROM THE ALZHEIMER’S ASSOCIATION INTERNATIONAL CONFERENCE 2025: ALZHEIMER’S ASSOCIATION RELEASES ITS FIRST CLINICAL PRACTICE GUIDELINE FOR BLOOD-BASED BIOMARKER TESTS

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

Cell Therapy Market to Reach USD 29.5 Billion by 2032, Growing at 21.5% CAGR | SkyQuest Technology Consulting

Rigel Announces Conference Call and Webcast to Report Second Quarter 2025 Financial Results and Business Update

Newsletter Signup

Explore

Press Releases

News & Opinion

Living

Others

Follow us